Merck v. Mylan: DPP-4 Inhibitor Patent Dispute Settled After Four Years
Merck Sharp & Dohme asserted two patents covering dipeptidyl peptidase-4 inhibitor formulations and metformin combinations against Mylan NV in West Virginia's Northern District. The case ran for 1,461 days before the parties reached a settlement while an appeal was pending at the Federal Circuit, requiring an indicative ruling under FRCP 62.1 to implement the agreed resolution.
Merck–Mylan DPP-4 Patent Fight Ends in Settlement on Appeal
Merck Sharp & Dohme Co., Inc. and Merck Sharp & Dohme, LLC filed suit on 2 May 2019 against Mylan NV and Mylan, Inc. in the United States District Court for the Northern District of West Virginia before Judge Thomas S. Kleeh. The action alleged infringement of US8414921B2, covering pharmaceutical compositions combining DPP-4 inhibitors with metformin, and US7326708B2, covering a phosphoric acid salt of a DPP-4 inhibitor — patents central to Merck's sitagliptin franchise.
The recorded basis of termination is 'Case Settled.' The docket order, styled as an indicative ruling under Federal Rule of Civil Procedure 62.1, states that by the time settlement was reached the district court had been divested of jurisdiction due to a pending Federal Circuit appeal, and that the court would grant a Rule 60(b) motion to amend its final judgment and enter a proposed Stipulated Modified Amended Final Judgment if the Federal Circuit were to remand for that limited purpose. The specific terms of the settlement are not disclosed in the available record.
The case ran for exactly 1,461 days — four years to the day — a timeline consistent with complex pharmaceutical patent litigation that progressed through trial and into appellate proceedings before resolution. The settlement-on-appeal posture, requiring the procedural mechanism of an indicative ruling, suggests the parties reached agreement after a district court judgment had already been entered. What drove the ultimate settlement, and whether it involved any product commercialisation terms, is not disclosed in the public record.
See Complete Case & Patent Analysis →Filing to Case Settled in 1461 days
1,461 days from filing to close — approximately 4 years, above average for a multi-patent ANDA/pharmaceutical district court dispute
US8414921B2 & US7326708B2 — DPP-4 Inhibitor Pharmaceutical Compositions
Any R&D or regulatory team developing a generic, biosimilar-adjacent, or combination oral antidiabetic product containing a DPP-4 inhibitor — particularly sitagliptin — or combining such an inhibitor with metformin should assess both patents before filing an ANDA or advancing a product into IND-stage development. The settlement-on-appeal resolution means no court has publicly narrowed the claim scope of either patent at the appellate level.
Official order — verbatim text
The indicative ruling under FRCP 62.1 reflects a narrow but important procedural posture: the district court had already entered a final judgment that was under active Federal Circuit review when the parties notified the court of settlement. The court's order does not resolve the merits of infringement or validity; it records only the court's willingness to amend its prior judgment upon remand to implement the agreed terms. The specific content of the Stipulated Modified Amended Final Judgment referenced as Exhibit A is not reproduced in the available record.
Case settled: what the agreed resolution means for both parties
Settlement while on appeal required FRCP 62.1 indicative ruling
Because the Federal Circuit appeal had divested the district court of jurisdiction, the parties could not simply file a consent order. Instead, the district court issued an indicative ruling under FRCP 62.1(a)(3), signalling it would enter the Stipulated Modified Amended Final Judgment upon a limited remand. This two-step mechanism is standard when trial-level settlement occurs after a notice of appeal has been filed.
FRCP 62.1 indicative rulingMerck secures negotiated resolution of two key sitagliptin patents
For Merck, settlement preserves the enforceability of US8414921B2 and US7326708B2 without the uncertainty of a Federal Circuit merits ruling on the appeal. A negotiated outcome at this stage typically allows the patent holder to shape the terms governing any generic entry, although the specific terms are not disclosed in the available record.
Patents remain in forceMylan avoids appellate ruling but faces negotiated constraints
Mylan's decision to settle while the Federal Circuit appeal was pending suggests the parties found a mutually acceptable path rather than awaiting an appellate decision on the merits. What obligations or permissions the settlement imposes on Mylan regarding the accused products is not disclosed in the available record.
Appellate risk avoidedDPP-4 inhibitor IP landscape shaped by private negotiation, not court ruling
Because the case settled before the Federal Circuit issued a merits ruling, no new precedent was created on DPP-4 inhibitor or metformin-combination patent validity or infringement. Other generic manufacturers assessing these patents cannot rely on a judicial ruling from this dispute; the IP risk position of US8414921B2 and US7326708B2 must be assessed independently.
No merits precedent setFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Merck Sharp & Dohme Co., Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Merck Sharp & Dohme, LLC | Company | Search in Eureka ↗ |
| Defendant | Mylan, NV | Company | /Search in Eureka ↗ |
| Co-Defendant | Mylan, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander S. Zolan | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Anthony Sheh | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bruce R. Genderson | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | David Krinsky | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Elise M. Baumgarten | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Frank X. Duff | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | James F. Companion | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jessamyn S. Berniker | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jihad Komis | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jingyuan Luo | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael W. Carey | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sandra K. Law | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarahi Uribe | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Shaun P. Mahaffy | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stanley E. Fisher | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven Robert Ruby | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff counsel | Vanessa Omoroghomwan | Attorney | Counsel for Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff law firm | Carey, Douglas, Kessler & Ruby, PLLC | Law Firm | Representing Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff law firm | Schrader Companion Duff & Law, PLLC | Law Firm | Representing Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff law firm | Schrader, Byrd & Companion, PLLC (Wheeling) | Law Firm | Representing Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff law firm | Williams & Connolly LLP | Law Firm | Representing Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Plaintiff law firm | Williams & Connolly LLP - Washington | Law Firm | Representing Merck Sharp & Dohme Co., Inc.Search in Eureka ↗ |
| Defendant counsel | Alissa M. Pacchioli | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Brian J. Sodikoff | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Deepro R. Mukerjee | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Gordon H. Copland | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Jillian M. Schurr | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Jitendra Malik | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Joseph M. Janusz | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Lance A. Soderstrom | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Matthew M. Holub | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | William J. O'Brien | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Alston & Bird LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Katten Muchin Rosenman LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Katten Muchin Rosenman LLP (Chicago) | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Katten Muchin Rosenman LLP (NC) | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Steptoe & Johnson PLLC - Bridgeport | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Presiding judge | Judge Thomas S Kleeh | Judge | West Virginia Northern District CourtSearch in Eureka ↗ |
R&D signals in the DPP-4 inhibitor and antidiabetic combination space
Patent activity from Merck and Mylan/Viatris around DPP-4 inhibitor formulations and metformin combinations reveals where innovation — and IP risk — is concentrating in oral diabetes therapy.
Merck's sitagliptin patent family extends beyond the asserted patents
US8414921B2 and US7326708B2 are two nodes in a broader Merck sitagliptin IP portfolio that includes method-of-treatment, polymorph, and dosage-form claims. Mapping the full family reveals expiry stagger, continuation risk, and where the franchise remains protected against ANDA challenge even as early patents age off.
Sitagliptin portfolio depthDPP-4 and metformin combination filing activity remains active
Fixed-dose combinations of DPP-4 inhibitors with metformin continue to generate patent filings from both innovator and generic companies, including novel formulation approaches, extended-release profiles, and co-crystal forms. Companies entering this space should map recent filings to identify freedom-to-operate windows and emerging design-around strategies.
Active filing spaceMylan/Viatris ANDA and patent filing activity in oral antidiabetics
Following the Mylan–Pfizer merger to form Viatris, the combined entity's ANDA pipeline and patent challenge activity in the DPP-4 inhibitor class warrants monitoring. Tracking Viatris's post-merger filing strategy can surface intended generic entry timelines and inform litigation risk assessments for branded DPP-4 holders.
Viatris ANDA pipelinePhosphoric acid salt and polymorph claim adjacencies may offer design-around space
US7326708B2's focus on the phosphoric acid salt form of a DPP-4 inhibitor leaves potential white space around alternative counterion forms, co-crystals, or amorphous dispersions not explicitly claimed. R&D teams exploring next-generation DPP-4 compound development should map this salt-form claim boundary to identify patentable alternatives.
Salt-form design-aroundSimilar DPP-4 inhibitor patent infringement cases in US district courts
Explore other pharmaceutical patent infringement disputes involving DPP-4 inhibitor compositions and ANDA challenges litigated in US federal district courts.
What this case signals for the pharmaceutical DPP-4 inhibitor IP landscape
A four-year, appeal-stage settlement in a branded-versus-generic DPP-4 patent dispute carries important signals for IP strategy teams in the diabetes therapeutics space.
DPP-4 inhibitor patents remain strategically enforceable post-settlement
The absence of a Federal Circuit merits ruling means US8414921B2 and US7326708B2 have not been adjudicated invalid or non-infringed. Any company developing sitagliptin-class generics or combination formulations should treat these patents as live enforcement risks and conduct independent FTO analysis.
Appeal-stage settlements preserve optionality but obscure the IP landscape
When pharmaceutical patent disputes settle after a district court judgment but before appellate resolution, the underlying claim constructions and invalidity findings may be modified or vacated as part of the settlement mechanism. Competitors relying on reported district court rulings in this case should verify whether those rulings remain operative.
Merck v Mylan — key questions answered
Merck Sharp & Dohme asserted two patents: US8414921B2, covering pharmaceutical compositions of DPP-4 inhibitors combined with metformin, and US7326708B2, covering the phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor. Both patents relate to Merck's sitagliptin franchise, marketed under brand names including Januvia and Janumet.
The recorded basis of termination is 'Case Settled.' The docket order is styled as an indicative ruling under FRCP 62.1, issued because the Federal Circuit appeal had divested the district court of jurisdiction at the time of settlement. The court stated it would enter the agreed Stipulated Modified Amended Final Judgment upon a limited remand. The specific terms of the settlement are not disclosed in the available record.
Federal Rule of Civil Procedure 62.1 allows a district court to issue an 'indicative ruling' when a motion is filed that the court lacks jurisdiction to grant because an appeal is pending. Here, because Mylan had appealed the district court's final judgment to the Federal Circuit, the district court was divested of jurisdiction and could not directly enter the settlement terms. The indicative ruling signals to the Federal Circuit that it should remand for that limited purpose.
Based on the available record, no Federal Circuit merits ruling on the validity or infringement of US8414921B2 or US7326708B2 is recorded in this case. The parties notified the Federal Circuit of their settlement and sought an indicative ruling from the district court, consistent with a resolution reached before appellate adjudication on the merits.
Because the case settled without a Federal Circuit merits ruling, no authoritative appellate claim construction or validity determination was published for US8414921B2 or US7326708B2. Other generic manufacturers cannot rely on a judicial ruling from this case to assess their own ANDA risk. An independent freedom-to-operate analysis against both patents remains necessary for any company developing DPP-4 inhibitor or sitagliptin-metformin combination products.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.